PT-141 results: what the clinical research actually shows

Last updated 2026-07-25

What did the PT-141 phase 3 trials actually measure?

The main evidence for bremelanotide comes from two identically designed phase 3 studies, both published together and often called the RECONNECT trials. They enrolled premenopausal women with hypoactive sexual desire disorder (HSDD) and randomized them to self-inject either bremelanotide 1.75 mg or placebo, as needed, before anticipated sexual activity ^[1]. The two co-primary endpoints were changes in the Female Sexual Function Index (FSFI) desire domain score and changes in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item measuring distress about low desire. Both are validated questionnaires, not lab measurements. There's no blood test or imaging scan that confirms desire went up; researchers rely entirely on what women report about their own experience ^[1]. That matters for how you read every number that follows. This is patient-reported outcome data, collected over 24 weeks, in a population that met specific diagnostic criteria for HSDD (more than low libido on any given week, and a persistent, distressing pattern) ^[2].

How much did desire actually improve compared to placebo?

Across the pooled RECONNECT studies, bremelanotide produced statistically significant improvements over placebo on both co-primary endpoints, but the absolute size of the effect was modest. A frequently cited responder analysis found that around 25% of women on bremelanotide reported a clinically meaningful increase in desire, compared to about 17% on placebo ^{[1] [3]}. Put another way: for roughly every 12 women treated, about one extra woman gets a meaningful benefit beyond what she'd have gotten from placebo alone. That's a real drug effect. It's also not dramatic, and independent reviewers have said so directly. A 2021 reanalysis of the phase 3 data in the Journal of Sex Research argued that when you look past the statistical significance and focus on effect size, the clinical meaningfulness of the improvement is questionable, and that the gap between drug and placebo, while real, is small in absolute terms ^[4]. A separate 2024 paper in the same journal, titled bluntly "Small Effects, Questionable Outcomes," made a similar argument about how the trial data get framed in marketing versus what the numbers show ^[5]. This doesn't mean the drug doesn't work. It means it works for some women, to a modest degree, and it doesn't work for others at all. Nobody has a way to predict in advance which group a given patient falls into. | Outcome measure | Bremelanotide | Placebo |

How is PT-141's mechanism different from Viagra or Addyi?

This is the single most important thing to understand about bremelanotide, and it's the reason it's approved for a different problem than erectile dysfunction drugs treat. Sildenafil (Viagra) and similar PDE5 inhibitors work on blood vessels. They relax smooth muscle and increase blood flow to genital tissue, which is a vascular, local mechanism. Bremelanotide does none of that. It's a melanocortin receptor agonist, meaning it binds to MC3R and MC4R receptors mostly in the brain, in circuits involved in motivation and sexual response ^{[7] [8]}. A 2022 review in CNS Spectrums lays out the neurobiological argument for why a centrally-acting drug is a logical treatment choice for HSDD, a condition that's fundamentally about the brain's desire circuitry rather than genital blood flow ^[9]. Melanocortin receptors, once known mainly for their roles in skin pigmentation and appetite regulation, also sit in hypothalamic pathways tied to sexual motivation ^[7] . Flibanserin (Addyi), the other FDA-approved HSDD drug, is also centrally acting but works differently, by modulating serotonin and dopamine/norepinephrine signaling daily as a pill. Bremelanotide is used on demand, as an injection, not daily. A 2021 commentary in Drug and Therapeutics Bulletin questioned whether either drug's approval set a good regulatory precedent, given how modest both effect sizes are relative to the side effect burden ^[10]. If you want the deeper mechanism explanation, including the melanocortin receptor pathway and dosing rationale, see our guide on PT-141 peptide.

What side effects showed up in the trials, and how common were they?

Nausea is the headline side effect, and it's not rare. Pooled safety data across the bremelanotide development program put nausea incidence at roughly 40%, making it by far the most common adverse event ^[6]. Flushing came in second, affecting around 20% of participants in various trial reports ^{[6] [2]}. Other reported effects included headache, injection site reactions, and vomiting in a smaller subset. A notable but infrequent finding was transient increases in blood pressure after dosing, which is part of why the drug isn't recommended for women with uncontrolled hypertension or known cardiovascular disease ^[11]. A distinct and less common effect is focal hyperpigmentation, darkening of small patches of skin, particularly on the face, gums, or breasts, seen in a minority of women with repeated dosing over time. This ties back to the melanocortin mechanism itself: MC1R activation in skin cells drives pigment production, so a drug acting broadly on melanocortin receptors can have this side effect as a side door consequence of hitting the same receptor family that governs melanin ^{[7] [8]}. Nausea tends to be worse with the first few doses and often lessens with repeated use, according to the safety pooling analysis, though it doesn't disappear entirely for everyone ^[6]. If nausea is severe, some prescribers suggest taking the dose on an empty stomach or timing it before sleep, though there's no formal trial data comparing these strategies head to head. For exact dosing details and how injections are timed relative to side effects, see PT-141 dosage and the practical walkthrough at PT-141 how to inject.

Does PT-141 cause weight loss or affect appetite?

This comes up because melanocortin receptors, especially MC4R, are heavily involved in appetite regulation, and MC4R agonism is an active area of obesity drug research entirely separate from bremelanotide's HSDD use ^[12]. A 2022 study in Diabetes, Obesity & Metabolism looked specifically at bremelanotide's effect on body weight in obese women across two phase 1 randomized controlled trials, finding evidence of an effect on body weight in this population . That's a real, published finding. It is not, however, evidence that bremelanotide is an effective or approved weight loss drug. The HSDD trials weren't designed to measure weight change as an outcome, the phase 1 obesity-focused studies used different populations and endpoints, and Vyleesi carries no FDA indication related to weight ^[2]. If you're chasing weight loss, this isn't a drug anyone should be reaching for on the strength of two phase 1 studies in a specific population.

What does 'first approval' actually mean for bremelanotide?

Bremelanotide, branded as Vyleesi, received FDA approval in 2019 for acquired, generalized HSDD in premenopausal women, making it only the second drug ever approved in the US specifically for low sexual desire in women, after flibanserin ^[13]. "Acquired" means the low desire developed after a period of normal desire, it wasn't lifelong. "Generalized" means it's not limited to a specific partner or situation. Both criteria matter because they define exactly who the trials enrolled, and by extension, who the approval covers. Bremelanotide is not approved for postmenopausal women, for men, or for situational low desire tied to a specific relationship or circumstance ^{[2] [13]}. A 2020 review in Pharmaceuticals covering the year's new peptide and oligonucleotide drug approvals (the "TIDES harvest") notes bremelanotide's approval as part of that broader wave of peptide therapeutics reaching market that year . It's also worth knowing that PT-141 was originally studied, and briefly investigated, as a tanning agent and for erectile dysfunction in men before its HSDD indication was pursued, reflecting the melanocortin system's dual role in pigmentation and sexual response ^{[8] [14]}.

Who actually responded best in the trials? Do subgroups matter?

A 2022 paper in the Journal of Women's Health ran prespecified and integrated subgroup analyses across the RECONNECT studies, breaking down response by factors like age, HSDD subtype, and baseline severity ^[3]. The short version: treatment effects were broadly consistent across the subgroups examined, without one obvious group that responded dramatically better or worse. That's a mildly reassuring finding in one sense (the drug doesn't seem to only work in a narrow slice of patients), but it also means there's no good way, based on current published data, to predict who out of two similar patients is more likely to be a responder. A separate phase 2b dose-ranging study looked at responder analyses across different doses and found the pattern of response supporting the 1.75 mg dose that eventually went to phase 3 and got approved ^[15].

How does PT-141 compare to flibanserin (Addyi) in the actual data?

Both drugs are FDA-approved for HSDD, both target brain-based mechanisms rather than blood flow, and both show real but modest effects over placebo in their respective trials. Neither is a dramatic fix, and clinicians reviewing both drugs have made that point directly in the literature ^{[10] [16]}. The practical differences matter more day to day. Flibanserin is a daily pill and carries an alcohol interaction warning plus a boxed warning about severe hypotension and syncope when combined with alcohol. Bremelanotide is an on-demand subcutaneous injection, used as needed before anticipated sexual activity, with its own distinct side effect profile centered on nausea and flushing rather than an alcohol interaction ^{[2] [16]}. A 2022 review in Current Psychiatry Reports covering pharmacotherapy options for female sexual dysfunction places both drugs in context alongside off-label options like bupropion and testosterone therapy, noting that none represent a large leap in efficacy over the others, each simply has a different risk and administration tradeoff ^[17].

What don't we know yet? Where are the evidence gaps?

The RECONNECT trials ran 24 weeks. That tells you something about short-to-medium term response, but it doesn't tell you much about what happens after a year or two of intermittent use, or whether tolerance to any of the effects (positive or negative) builds over time ^{[1] [2]}. The approved indication is narrow: premenopausal women with acquired, generalized HSDD. That leaves large groups understudied in the main trials, including postmenopausal women, men, and anyone whose low desire is tied to a specific relationship context rather than being generalized ^[13]. A 2023 review in Expert Opinion on Pharmacotherapy evaluating bremelanotide's overall place in HSDD treatment reinforces that while it fills a real treatment gap, the effect size and the narrowness of the studied population mean it's one option among a short list, not a definitive solution ^[18]. A 2025 review in Clinical Obstetrics and Gynecology covering novel pharmacologic treatments for female sexual dysfunction similarly frames the field as still actively evolving, with newer approaches and combination strategies under active study ^[14]. There's also a smaller, separate research thread worth flagging honestly: a 2024 paper in Anticancer Research examined bremelanotide's effect on glioblastoma cells in a lab setting, finding it induced cell death via suppression of survivin expression . This is preclinical, in-vitro cancer biology research, completely unrelated to the HSDD indication, and it has no bearing on how the drug is used clinically for desire. It's mentioned here only because it shows up in literature searches and shouldn't be confused with anything relevant to sexual health dosing.

What do the trial results mean for cycle length and how long to try it?

Since bremelanotide is dosed as-needed rather than daily, the concept of a "cycle" works differently than with something like flibanserin. The 24-week trial window is the best evidence anchor for how long a reasonable trial period should run before deciding whether it's working for you ^[1]. Given that around 1 in 4 women were meaningful responders in trials versus roughly 1 in 6 on placebo, a portion of any group won't notice a difference even with consistent, correct use over months ^{[1] [3]}. That's worth knowing going in, so you're not chasing a benefit that the population-level data suggests may not materialize. For practical guidance on how long a typical evaluation period runs and how usage patterns are structured, see our page on PT-141 cycle length. If you want to understand why the injection is timed the way it is relative to how long the drug stays active, PT-141 half life covers the pharmacokinetics side of that question.

Is PT-141 safe for women with high blood pressure or heart conditions?

This deserves a direct, non-hedged answer: caution is warranted. Bremelanotide has been shown to cause transient increases in blood pressure after dosing, and a 2022 review in Medicina specifically addressed the management challenge of prescribing sexual dysfunction treatments, including bremelanotide, in women who also have hypertension ^[11]. Because of this, it isn't recommended for women with uncontrolled high blood pressure or known cardiovascular disease, and it should be used with real caution, under medical supervision, in anyone with borderline or treated hypertension ^[11]. This is exactly why bremelanotide should be provider-reviewed rather than self-directed. A qualified prescriber can check baseline blood pressure, review a full medical history, and decide whether the transient BP effect is a meaningful risk for a specific patient before any prescription is written or filled through a pharmacy partner.

Frequently asked questions

What percentage of women saw results with PT-141 in clinical trials?

In the pooled phase 3 RECONNECT trials, about 25% of women taking bremelanotide reported a clinically meaningful increase in desire, compared to about 17% on placebo ^[1][15]. That's a real but modest difference, meaning most women in both groups did not report that level of meaningful change over the 24-week study period.

How is PT-141's mechanism different from Viagra?

Viagra (sildenafil) works on blood vessels, increasing genital blood flow through a vascular mechanism. PT-141 (bremelanotide) works centrally, activating melanocortin receptors (mainly MC3R and MC4R) in brain circuits tied to sexual motivation, not blood flow ^[3][18]. That's why it's approved for low desire rather than erectile or arousal blood-flow problems.

What are the most common PT-141 side effects in the research?

Nausea is the most common, reported in roughly 40% of participants across pooled safety data. Flushing follows at around 20%. Headache, injection site reactions, and transient blood pressure increases were also reported, along with rare focal skin darkening with repeated use ^[2].

Does PT-141 cause nausea in everyone who takes it?

No, but it's common: roughly 40% of trial participants reported nausea, making it the most frequently reported side effect in the safety pooling data ^[2]. It tends to be more pronounced with early doses and may lessen with continued use, though it doesn't resolve for every patient.

Is PT-141 (bremelanotide) FDA approved, and for what exactly?

Yes. Bremelanotide, sold as Vyleesi, was FDA approved in 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women ^[5]. It is not approved for postmenopausal women, men, or situational low desire tied to a specific partner or circumstance.

How does PT-141 compare to flibanserin (Addyi)?

Both are FDA-approved, centrally-acting HSDD drugs with modest but real effects over placebo. Flibanserin is a daily pill with an alcohol interaction warning; bremelanotide is an as-needed injection with nausea and flushing as its main side effects instead ^[4][12][19]. Neither shows a dramatically larger effect than the other in published reviews.

Can PT-141 cause weight loss?

A 2022 phase 1 study found an effect on body weight in obese women taking bremelanotide, tied to its action on MC4R appetite-related receptors ^[24]. This isn't an approved use, though, and the HSDD trials that led to FDA approval didn't study or claim weight loss as an outcome.

Is PT-141 safe for someone with high blood pressure?

It requires caution. Bremelanotide can cause transient increases in blood pressure after dosing, so it isn't recommended for women with uncontrolled hypertension or cardiovascular disease, and needs medical supervision in anyone with borderline or treated blood pressure issues ^[21]. This is a conversation to have directly with a prescriber.

Why does PT-141 cause skin darkening in some people?

Bremelanotide activates melanocortin receptors broadly, including MC1R, which drives melanin production in skin cells. This is the same receptor family responsible for tanning, so a minority of women using the drug repeatedly report focal hyperpigmentation, usually on the face, gums, or breasts ^[3][6].

How long do the PT-141 clinical trials say it takes to see results?

The main RECONNECT trials ran 24 weeks, and that's the best evidence-based window for evaluating whether the drug is working for you, since that's the timeframe over which meaningful responder rates were measured ^[1]. There's no strong published data on effects beyond that window.

Does PT-141 work for men too, or only women?

It's FDA-approved only for premenopausal women with HSDD ^[5]. Bremelanotide was originally studied for erectile dysfunction in men before its current indication was pursued, and the melanocortin mechanism itself isn't sex-specific, but there's no FDA-approved male indication, and the trial evidence discussed here is specific to women ^[6][14].

Are PT-141 results the same as what flibanserin studies showed?

Roughly, yes, in terms of effect size: both drugs show statistically real but modest improvements over placebo, and independent reviewers have raised similar concerns about how clinically meaningful the absolute differences are for either drug ^[12][16]. They differ mainly in mechanism, dosing schedule, and side effect profile, not in the general magnitude of benefit.

What did independent researchers say about the PT-141 trial data?

Some independent reanalyses have pushed back on how the phase 3 results are framed. A 2021 Journal of Sex Research reanalysis and a 2024 follow-up titled "Small Effects, Questionable Outcomes" both argue the absolute clinical benefit, while statistically real, is smaller than marketing suggests ^[11][16].

Sources

1. Obstetrics and Gynecology, 2019 (PMID 31599840): The two phase 3 RECONNECT trials used FSFI desire domain and FSDS-DAO as co-primary endpoints, with roughly 25% of bremelanotide users reporting meaningful improvement versus about 17% on placebo, over a 24-week trial period.
2. Journal of Women's Health, 2022 (PMID 35147466): Pooled safety data across the bremelanotide clinical development program found nausea in roughly 40% and flushing in around 20% of participants, with hyperpigmentation and transient blood pressure increases also reported.
3. Nature Reviews Endocrinology, 2023 (PMID 37365323): Melanocortin receptors (MC3R, MC4R) in the central nervous system are targets for metabolic and behavioral regulation, distinct from vascular mechanisms.
4. The Annals of Pharmacotherapy, 2020 (PMID 31893927): Bremelanotide's approval was specific to acquired, generalized HSDD in premenopausal women, distinguishing it from vascular-acting sexual dysfunction drugs.
5. Drugs, 2019 (PMID 31429064): Bremelanotide (Vyleesi) received its first FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women.
6. Bremelanotide, 2006 (PMID 31369224): Bremelanotide was originally investigated as a tanning agent and for male erectile dysfunction due to its melanocortin receptor activity before its HSDD indication was developed.
7. Effect of bremelanotide on body weight of obese women, Diabetes Obesity & Metabolism, 2022 (PMID 35170192): MC4R is heavily involved in appetite regulation, forming the basis for studying bremelanotide's effect on body weight.
8. Current Psychiatry Reports, 2022 (PMID 35102537): A review of pharmacotherapy options for female sexual dysfunction places bremelanotide and flibanserin alongside off-label options, noting neither shows dramatically superior efficacy.
9. Journal of Sex Research, 2024 (PMID 36809187): A 2024 analysis titled 'Small Effects, Questionable Outcomes' argues that bremelanotide's clinical benefit over placebo, while statistically real, is small and its framing in marketing overstates clinical meaningfulness.
10. Drug and Therapeutics Bulletin, 2021 (PMID 34642243): A commentary questions the regulatory precedent for both bremelanotide and flibanserin approvals given their modest effect sizes relative to side effect burden.
11. Expert Opinion on Pharmacotherapy, 2023 (PMID 36242769): An evaluation of bremelanotide injection concludes it fills a real treatment gap for HSDD but is one option among a limited list given its effect size and narrow studied population.
12. Clinical Obstetrics and Gynecology, 2025 (PMID 39846877): A 2025 review of novel pharmacologic treatments for female sexual dysfunction frames the field as still evolving, including work on drugs outside the approved premenopausal HSDD population.
13. Journal of Women's Health, 2022 (PMID 35230162): Prespecified and integrated subgroup analyses from the RECONNECT phase 3 studies found broadly consistent treatment effects across subgroups defined by age, HSDD subtype, and baseline severity.
14. Journal of Sex Research, 2021 (PMID 33678061): A reanalysis of phase 3 bremelanotide trial data questions the clinical meaningfulness of the improvement over placebo despite statistical significance.
15. The Journal of Sexual Medicine, 2019 (PMID 31277966): A phase 2b dose-ranging responder analysis supported the 1.75 mg dose that was later used in phase 3 trials and approved by the FDA.
16. CNS Spectrums, 2022 (PMID 33455598): A neurobiological review explains why a centrally-acting drug targeting brain desire circuitry is a logical mechanism for treating HSDD.
17. Medical Letter on Drugs and Therapeutics, 2019 (PMID 31381550): An independent drug bulletin review compares bremelanotide's administration and side effect profile against flibanserin for HSDD treatment.
18. Medicina (Kaunas), 2022 (PMID 35630054): Management of sexual dysfunction treatment, including bremelanotide, requires caution in women with hypertension due to transient blood pressure increases after dosing.
19. Pharmaceuticals (Basel), 2020 (PMID 32151051): Bremelanotide's 2019 approval is noted as part of that year's wave of new peptide and oligonucleotide drug approvals in the US.
20. Biomolecules, 2022 (PMID 36291616): Melanocortin receptor ligands have roles extending beyond pigmentation and adrenal signaling, including behavioral and sexual response pathways.
21. Anticancer Research, 2024 (PMID 39197897): A 2024 preclinical study found bremelanotide induced cell death in glioblastoma cells via suppression of survivin expression, unrelated to its HSDD clinical use.